The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management
Open accessAbstract
The sickle hemoglobin is an abnormal hemoglobin due to point mutation (GAG → GTG) in exon 1 of the β globin gene resulting in the substitution of glutamic acid by valine at position 6 of the β globin polypeptide chain. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of sickle cell disease in general and sickle cell anemia in particular. The disease itself is chronic in nature but many of its complications are acute such as the recurrent acute painful crises (its hallmark), acute chest syndrome, and priapism. These complications vary considerably among patients, in the same patient with time, among countries and with age and sex. To date, there is no well-established consensus among providers on the management of the complications of sickle cell disease due in part to lack of evidence and in part to differences in the experience of providers. It is the aim of this paper to review available current approaches to manage the major complications of sickle cell disease. We hope that this will establish another preliminary forum among providers that may eventually lead the way to better outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 1×
“Patients who responded to hydroxyurea experienced significant reduction in the incidence of acute painful episodes, acute chest syndrome, transfusion requirement, and mortality [473, 474, 476].”
BackgroundCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Self-citationDevelopment of a PROMIS item bank to measure pain interference
Amtmann, D., Cook, K. F., Jensen, M. P., Chen, W.-H., Choi, S., Revicki, D., Cella, D., Rothrock, N., Keefe, F., Callahan, L., et al. (2010) · Pain · doi:10.1016/j.pain.2010.04.025 · Cited by 1,199
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
McGrath, P. J., Walco, G. A., Turk, D. C., Dworkin, R. H., Brown, M. T., Davidson, K., Eccleston, C., Finley, G. A., Goldschneider, K., Haverkos, L., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.04.007 · Cited by 851 · cited 1×
“A substantial literature exists that describes pain characteristics in school-age children (>6 years) and adolescents, and recommendations have been made for appropriate pediatric assessment instruments [401, 402].”
BackgroundWang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803 · cited 1×
“Although hydroxyurea was first approved for adults with sickle cell anemia and sickle-β0thalassemia, results of the recently described Baby HUG trial justify its use in children as well [475].”
BackgroundSelf-citationKato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661 · cited 1×
“Recent studies have proposed an association between hemolysis-induced vasculopathy and a hemolytic subphenotype in SCD that presents clinically with increased incidence of leg ulcers, pulmonary hypertension, and priapism [245].”
BackgroundThe natural history of stroke in sickle cell disease
Powars, D., Wilson, B., Imbus, C., Pegelow, C., & Allen, J. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90772-6 · Cited by 594 · cited 1×
“Moreover, many adult patients and their providers choose to discontinue transfusion given its associated morbidities, including alloimmunization, iron overload, and infection [284, 285].”
BackgroundAcute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course
Vichinsky, E. P., Styles, L. A., Colangelo, L. H., Wright, E. C., Castro, O., Nickerson, B., & Disease, T. C. S. O. S. C. (1997) · Blood · doi:10.1182/blood.v89.5.1787 · Cited by 573 · cited 1×
“It is about three times more common in young children than in adults but more severe in adults [478, 479].”
BackgroundOutcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
Blake, G. M., & Fogelman, I. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2007.057505 · Cited by 532 · cited 1×
“5 standard deviations (T score) below the peak bone mass typically achieved by a healthy adult between the ages of 18–30 years of age of the same sex and ethnicity [175] (WHO Scientific Group on Prevention and Management of Osteoporosis 2000: Geneva, Switzerland, 2003.”
BackgroundPrediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508
Self-citationAdverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496 · cited 1×
“In adults, however, bisphosphonates are widely used for secondary OP with acceptable efficacy and tolerability [184, 185].”
BackgroundPalermo, T. M., Eccleston, C., Lewandowski, A. S., de C. Williams, A. C., & Morley, S. (2010) · Pain · doi:10.1016/j.pain.2009.10.004 · Cited by 489
Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Chevret, S., Hau, I., Coïc, L., Leveillé, E., Lemarchand, E., Lesprit, E., et al. (2011) · Blood · doi:10.1182/blood-2010-06-293514 · Cited by 336
Silent cerebral infarcts in sickle cell anemia: a risk factor analysis
Kinney, T. R., Sleeper, L. A., Wang, W. C., Zimmerman, R. A., Pegelow, C. H., Ohene-Frempong, K., Wethers, D. L., Bello, J. A., Vichinsky, E. P., Moser, F. G., et al. (1999) · PEDIATRICS · doi:10.1542/peds.103.3.640 · Cited by 309
Self-citationVichinsky, E. P. (2010) · JAMA · doi:10.1001/jama.2010.562 · Cited by 296
Miller, S. T., Macklin, E. A., Pegelow, C. H., Kinney, T. R., Sleeper, L. A., Bello, J. A., DeWitt, L. D., Gallagher, D. M., Guarini, L., Moser, F. G., et al. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.117580 · Cited by 287
Self-citationIncentive Spirometry to Prevent Acute Pulmonary Complications in Sickle Cell Diseases
Bellet, P. S., Kalinyak, K. A., Shukla, R., Gelfand, M. J., & Rucknagel, D. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509143331104 · Cited by 278
Dobson, S. R., Holden, K. R., Nietert, P. J., Cure, J. K., Laver, J. H., Disco, D., & Abboud, M. R. (2002) · Blood · doi:10.1182/blood.v99.9.3144 · Cited by 277 · cited 1×
“Moya-moya syndrome has been increasingly recognized following stroke in children with sickle cell anemia and has been associated with intellectual decline, particularly in performance IQ [308], as well as a markedly increased risk for subsequent cerebrovascular event (stroke or transient ischemic attack (TIA)) [309].”
BackgroundLaboratory profile of sickle cell disease: a cross-sectional analysis
STEWARTWEST, M. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90073-v · Cited by 136
Bone status in a mouse model of genetic hemochromatosis
Guggenbuhl, P., Fergelot, P., Doyard, M., Libouban, H., Roth, M.-P., Gallois, Y., Chalès, G., Loréal, O., & Chappard, D. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1456-2 · Cited by 76
'Acute Chest Syndrome' in Adults With Sickle Cell Anemia: Microbiology, Treatment, and Prevention
Charache, S. (1979) · Archives of Internal Medicine · doi:10.1001/archinte.1979.03630380047016
Cited by
Sickle cell pain: a critical reappraisal
Ballas, S. K., Gupta, K., & Adams-Graves, P. (2012) · Blood · doi:10.1182/blood-2012-04-383430 · Cited by 445
Self-citationSickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment
Inusa, B., Hsu, L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K., & Atoyebi, W. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5020020 · Cited by 313
Metadata
- Authors
- Ballas, S. K., Kesen, M. R., Goldberg, M. F., Lutty, G. A., Dampier, C., Osunkwo, I., Wang, W. C., Hoppe, C., Hagar, W., Darbari, D. S., & Malik, P.
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-55
- ISSN
- 1537-744X (ISSN-L)
- OpenAlex
- W2040983608
- Cited by
- 195
- References
- 26
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.